- Home
- ACTU
as 12-24-2024 4:00pm EST
Stocks
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 153.1M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 74.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.51 - $10.16 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ACTUATE THERAPEUTICS INC News
ACTU Breaking Stock News: Dive into ACTU Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
a month ago
Actuate Therapeutics to be Added to Russell 2000® Index
GlobeNewswire
a month ago
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
GlobeNewswire
2 months ago
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development
GlobeNewswire
3 months ago
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
GlobeNewswire
3 months ago
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
GlobeNewswire
3 months ago
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
GlobeNewswire
4 months ago
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Compare ACTU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACTU ACTUATE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.